Connect with Us at the Upcoming Events

Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!

Book a Meeting

Anti-Mouse MBL-A Monoclonal Antibody (clone 8G6) -0.5 mg (CAT#: CB-P405-K) Datasheet

Product Type
Antibody
Description
Mannose-binding lectin (MBL), also known as mannose-binding protein (MBP), is a calcium-dependent oligomeric protein that belongs to the collectin family of proteins. It contains a collagen-like domain and a carbohydrate recognition domain, Enabling MBL to recognize carbohydrates (for example, MBL can activate complement pathways that are not related to classical and alternative complement activation pathways by using linked mannose-binding lectin-associated serine protease (MASP-2) in antibodies and C1q-. MASP- 2 Allow C4 and C2 to be cleaved to form C3 convertase. Once bound, MBL exhibits complement-dependent antibacterial activity, such as microbial opsonization and/or microbial lysis through membrane attack complexes, thus innate immunity.
In humans, MBL is encoded by a single gene, while in mice, there are two homologous proteins called MBL-A and MBL-C. The concentration of MBL-A in serum is about 6 times lower than that of MBL-C. In casein and LPS injection models, MBL-A is an acute phase protein, but not MBL-C. In addition, MBL-A-deficient mice have been shown to have abnormal antigen-specific IgM responses and increased sensitivity to infection. Please note that monoclonal antibody 8G6 is a calcium-dependent antibody.
Size
100 µg

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK